ALT Stock Analysis: Altimmune | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 615m USD | 12M Return: -31.8% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 11.6M
Qual. Beats: 1
Rev. Trend: -73.2%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Altimmune, Inc. is a late clinical stage biopharmaceutical company developing novel therapies for serious liver diseases. Its lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist currently in Phase 3 clinical trials for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland, and trades on NASDAQ under the ticker ALT.
As a clinical stage biopharmaceutical company, Altimmune operates within a high-risk, capital-intensive business model that depends on successful clinical trial outcomes and eventual regulatory approval to generate revenue, with most such companies incurring significant R&D expenses prior to commercialization. The GLP-1 receptor agonist class has become one of the most actively pursued therapeutic areas in biotechnology, driven by demonstrated efficacy in metabolic and weight-related conditions.
- Pemvidutide Phase 3 MASH trial data readout approaches
- Rezdiffra competition pressures pemvidutide market opportunity
- Capital raise likely needed to fund Phase 3 development
| Net Income: -91.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.23 > 0.02 and ΔFCF/TA 25.38 > 1.0 |
| NWC/Revenue: 898k% < 20% (prev 727k%; Δ 171k% < -1%) |
| CFO/TA -0.21 > 3% & CFO -71.6m > Net Income -91.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 29.56 > 1.5 & < 3 |
| Outstanding Shares: last quarter (124.5m) vs 12m ago 64.75% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.01% > 50% (prev 0.01%; Δ 0.00% > 0%) |
| Interest Coverage Ratio: -32.70 > 6 (EBIT TTM -88.4m / Interest Expense TTM 2.70m) |
| A: 0.96 (Total Current Assets 334.7m - Total Current Liabilities 11.3m) / Total Assets 335.6m |
| B: -2.00 (Retained Earnings -672.0m / Total Assets 335.6m) |
| C: -0.36 (EBIT TTM -88.4m / Avg Total Assets 246.4m) |
| D: 5.50 (Book Value of Equity 284.0m / Total Liabilities 51.6m) |
| Altman-Z'' = 3.16 = A |
| DSRI: 0.38 (Receivables 1.67m/2.46m, Revenue 36.0k/20.0k) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.22 (AQ_t 0.00 / AQ_t-1 0.01) |
| SGI: 1.80 (Revenue 36.0k / 20.0k) |
| TATA: -0.06 (NI -91.1m - CFO -71.6m) / TA 335.6m) |
| Beneish M = -3.44 (Cap -4..+1) = AA |
As of July 08, 2026, the stock is trading at USD 3.02 with a total of 4,553,694 shares traded. Over the past week, the price has changed by +2.72%, over one month by +10.62%, over three months by -10.65% and over the past year by -31.83%.
Current recommended Stop Loss: 2.80 (which is 7.3% or 1.3 ATR below the current price).
Altimmune has received a consensus analysts rating of 4.44. Therefore, it is recommended to buy ALT.
- StrongBuy: 5
- Buy: 3
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 15.5 | 411.6% |
P/E Forward = 8.1766
P/S = 17070.51
P/B = 2.1708
P/EG = 32.6168
Revenue TTM = 36.0k USD
EBIT TTM = -88.4m USD
EBITDA TTM = -88.3m USD
Long Term Debt = 34.5m USD (from longTermDebt, last quarter)
Short Term Debt = 265k USD (from shortTermDebt, last quarter)
Debt = 37.2m USD (from shortLongTermDebtTotal, last quarter) + Leases 1.34m
Net Debt = -282.6m USD (calculated: Debt 37.2m - CCE 319.8m)
Enterprise Value = 331.9m USD (614.5m + Debt 37.2m - CCE 319.8m)
Interest Coverage Ratio = -32.70 (Ebit TTM -88.4m / Interest Expense TTM 2.70m)
EV/FCF = -4.39x (Enterprise Value 331.9m / FCF TTM -75.6m)
FCF Yield = -22.77% (FCF TTM -75.6m / Enterprise Value 331.9m)
FCF Margin = -210k% (FCF TTM -75.6m / Revenue TTM 36.0k)
Net Margin = -253k% (Net Income TTM -91.1m / Revenue TTM 36.0k)
Gross Margin = unknown ((Revenue TTM 36.0k - Cost of Revenue TTM 15.0m) / Revenue TTM)
Tobins Q-Ratio = 0.99 (Enterprise Value 331.9m / Total Assets 335.6m)
Interest Expense / Debt = 7.27% (Interest Expense 2.70m / Debt 37.2m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -69.8m (EBIT -88.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 26.04 (Total Current Assets 334.7m / Total Current Liabilities 12.9m)
Debt / Equity = 0.13 (Debt 37.2m / totalStockholderEquity, last quarter 284.0m)
Debt / EBITDA = 3.20 (negative EBITDA) (Net Debt -282.6m / EBITDA -88.3m)
Debt / FCF = 3.74 (negative FCF - burning cash) (Net Debt -282.6m / FCF TTM -75.6m)
Total Stockholder Equity = 214.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -36.96% (Net Income -91.1m / Total Assets 335.6m)
RoE = -42.57% (Net Income TTM -91.1m / Total Stockholder Equity 214.0m)
RoCE = -35.57% (EBIT -88.4m / Capital Employed (Equity 214.0m + L.T.Debt 34.5m))
RoIC = -21.51% (negative operating profit) (NOPAT -69.8m / Invested Capital 324.6m)
WACC = 12.53% (E(614.5m)/V(651.7m) * Re(12.94%) + D(37.2m)/V(651.7m) * Rd(7.27%) * (1-Tc(0.21)))
Discount Rate = 12.94% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 39.93%
[DCF] Fair Price = unknown (Cash Flow -75.6m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 2.35 | # QB: 1
Revenue Correlation: -73.17 | Revenue CAGR: -68.98% | SUE: -0.08 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.16 | Chg30d=+1.81% | Revisions=+67% | Analysts=7
EPS next Quarter (2026-09-30): EPS=-0.17 | Chg30d=+5.43% | Revisions=+67% | Analysts=7
EPS current Year (2026-12-31): EPS=-0.71 | Chg30d=+4.24% | Revisions=+67% | GrowthEPS=+29.1% | GrowthRev=-90.0%
EPS next Year (2027-12-31): EPS=-0.86 | Chg30d=+4.78% | Revisions=+67% | GrowthEPS=-21.2% | GrowthRev=-100.0%
[Analyst] Revisions Ratio: +89% (up=24, down=0)